Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Clot-Busting devices aim to save limbs and lives

NCT ID NCT07350499

Disease control Sponsor: Imperative Care, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This study is testing two catheter-based devices, Symphony and Prodigy, that remove blood clots from blood vessels in the legs, arms, or lungs. Researchers want to see if these devices can safely restore blood flow and prevent serious outcomes like amputation or heart strain. The trial will follow 750 adults for up to 30 days to check how well the devices work and if there are any complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Symphony and Prodigy thrombectomy systems (catheter-based devices that remove blood clots)
What this could lead to
If successful, these devices could offer a safer, more effective way to remove dangerous blood clots, potentially reducing the need for major surgery or long-term disability.
What could go wrong
This is an early-stage study with 750 participants, so results may not apply to everyone. There are risks of bleeding, vessel damage, or the device not fully clearing the clot.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll subjects aged 18 years and older who are undergoing endovascular procedures in the peripheral or pulmonary vasculature systems where, in the opinion of the treating physician, Imperative Care devices are appropriate for use within their cleared indications. All subjects must meet the general eligibility criteria and provide written informed consent prior to any study-specific data collection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is ≥ 18 years of age 2. Subject is willing and able to comply with the follow-up schedule specified in this protocol 3. Subject is willing and able to provide written informed consent prior to any study-related data collection 4. Subject has a planned procedure, involving the use of Imperative Care vascular devices within their intended use Exclusion Criteria: 1. Subjects with any contraindications per the applicable Instructions for Use 2. Subject with life expectancy of less than 1 year 3. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with Imperative Care devices 4. Subject who may be unable to complete study follow-up 5. Peripheral Venous Cohort ONLY: Presence of thrombus extending more than 2 cm into the IVC on imaging

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arterial occlusion pulmonary embolism Thromboembolism thrombotic disease venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial thromboembolism Pulmonary embolism Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BayCare Health - St. Joseph Hospital

    RECRUITING

    Tampa, Florida, 33607, United States

  • Huntsville Hospital

    RECRUITING

    Huntsville, Alabama, 35801, United States

  • Mercy Health

    RECRUITING

    Cincinnati, Ohio, 45242, United States

  • Midwest Cardiovascular Institute

    RECRUITING

    Naperville, Illinois, 60540, United States

  • Mount Sinai Hospital

    RECRUITING

    New York, New York, 10029, United States

  • Profound Research

    RECRUITING

    Munster, Indiana, 46321, United States

  • Sentara Norfolk General Hospital

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • University At Buffalo

    RECRUITING

    Buffalo, New York, 14203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.